“Tirzepatide is the first investigational medicine to deliver more than 20 percent weight loss on average in a phase 3 study, reinforcing our confidence in its potential to help people living with obesity,”
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor, and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body’s receptors for GIP and GLP-1, two natural incretin hormones. Cyanocobalamin will help increase energy.
It acts on a hormone called GLP-1, which controls appetite, so patients taking the drug feel more full. Tirzapetide uniquely also acts on another hormone related to insulin too.